Wedbush Reiterates Underperform on Eikon Therapeutics, Maintains $7 Price Target

Wedbush analyst Robert Driscoll has reiterated an 'Underperform' rating on Eikon Therapeutics (NASDAQ: EIKN) and has maintained a price target of $7 for the stock.